Special Edition: What's Next—Oral GLP-1 Receptor Agonists

Special Edition: What's Next—Oral GLP-1 Receptor Agonists

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support from Novo Nordisk.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham.

Selected references:

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(100)

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates ...

17 Aug 33min

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Aug 35min

Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!

Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!

Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease...

10 Aug 32min

Special Edition: Hypertension Part I—Overview and Management

Special Edition: Hypertension Part I—Overview and Management

In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure....

6 Aug 33min

Special Edition: Highlights from the ADA's 2026 Scientific Sessions

Special Edition: Highlights from the ADA's 2026 Scientific Sessions

In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On ...

30 Juli 44min

Special Edition: Lp(a) & CV Risk

Special Edition: Lp(a) & CV Risk

Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing unders...

24 Juli 34min

Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations

Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations

Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therap...

17 Juli 25min

Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available ...

7 Juli 28min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
bullfika
rss-vuxna-pa-latsas
inga-beiga-morsor
johannes-hansen-podcast
angestpodden
sexnoveller-deluxe
not-fanny-anymore
rss-viktmedicinpodden
sova-med-dan-horning
sa-in-i-sjalen
hacka-livet
rss-autismandan
rss-hos-psykologen
halsoveckan-by-tyngre
tyngre-traningssnack
tyngre-radio
rss-basta-livet
medicinvetarna